Stockscreener 앱 받기
3.31
0.90%
-0.03
전일 마감가:
$3.34
열려 있는:
$3.34
하루 거래량:
4.46M
Relative Volume:
1.22
시가총액:
$403.83M
수익:
$58.36M
순이익/손실:
$-25.72M
주가수익비율:
-9.0909
EPS:
-0.3641
순현금흐름:
$-24.91M
1주 성능:
-15.35%
1개월 성능:
-43.13%
6개월 성능:
-17.87%
1년 성능:
+7.12%
1일 변동 폭
$3.26
$3.39
1주일 범위
$3.21
$3.91
52주 변동 폭
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.31 | 407.49M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
Faruqi & Faruqi Investigates Aquestive Therapeutics After 40% Stock Plunge Due to FDA Concerns - Intellectia AI
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - PR Newswire
Shorts Report: Is Aquestive Therapeutics Inc backed by strong institutional buyingQuarterly Investment Review & Verified Technical Trade Signals - baoquankhu1.vn
Kaplan Fox & Kilsheimer LLP is Investigating Aquestive Therapeutics, Inc. (AQST) for Potential Securities Law Violations - NewMediaWire
About Us - FinancialContent
Peering Into Aquestive Therapeutics Inc's Recent Short Interest - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc.AQST - PR Newswire
A Look At Aquestive Therapeutics (AQST) Valuation After Anaphylm Regulatory Update And FDA Feedback - Sahm
Commonwealth Equity Services LLC Takes $5.92 Million Position in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Rate Hike: Is Aquestive Therapeutics Inc gaining market share2025 Price Momentum & Low Drawdown Trading Strategies - baoquankhu1.vn
Levi & Korsinsky Investigates Possible Securities Fraud by Aquestive Therapeutics, Inc. (AQST) - marketscreener.com
Here's Why Aquestive Therapeutics (AQST) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Trend Review: How does Aquestive Therapeutics Inc score in quality rankingsJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - baoquankhu1.vn
User - FinancialContent
Aquestive Therapeutics Inc. (AQST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aquestive Therapeutics Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through the Firm's Investigation - TradingView — Track All Markets
Aquestive drops as FDA flags issues in Anaphylm marketing application - MSN
Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle - Seeking Alpha
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - marketscreener.com
Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround - Your Wyoming Link
Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies in Anaphylm FilingWhat's Changed - Sahm
Assessing Aquestive Therapeutics (AQST) Valuation After FDA Flags Anaphylm Application Deficiencies - Yahoo Finance
Oklo, Applied Digital, Opendoor Technologies, Vistra, Aquestive Therapeutics: Stocks making the biggest moves today - MSN
Why Aquestive Therapeutics (AQST) Is Down 39.4% After FDA Flags Deficiencies In Anaphylm Application – And What's Next - Yahoo Finance
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet - Benzinga
AQST Stock Plunges On An FDA Setback For Its Allergy Drug – Here’s What Has Changed - Stocktwits
Sector Update: Health Care - MarketScreener
Aquestive Therapeutics Stock Dips Amid Financial Challenges - StocksToTrade
Oklo, Applied Digital, Opendoor Technologies, Vistra, Aquestive Therapeutics: Stocks Making The Biggest Moves Today - Stocktwits
INVESTOR ALERT: Investigation of Aquestive Therapeutics, Inc. (AQST) by Holzer & Holzer, LLC - GlobeNewswire
Is Aquestive Therapeutics Inc. stock oversold or undervalued2025 Price Targets & Accurate Entry and Exit Point Alerts - ulpravda.ru
What's Going On With ARS Pharmaceuticals Stock Friday?ARS Pharmaceuticals (NASDAQ:SPRY) - Benzinga
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Sahm
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Aquestive Therapeutics Sees Unusually Large Options Volume (NASDAQ:AQST) - MarketBeat
FDA Identifies NDA Deficiencies for Anaphylm as Review Continues, Aquestive Therapeutics Announces - Patient Care Online
BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies ... - Bluefield Daily Telegraph
BREAKING: Aquestive Therapeutics Investigated for Securities Fraud After FDA Identifies Deficiencies; Investors Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewswire
Aquestive Therapeutics Faces Turbulent Market While Strategizing for Future Growth - timothysykes.com
FDA identifies deficiencies in Aquestive’s Anaphylm application By Investing.com - Investing.com Nigeria
FDA setback for Aquestive Thera’s Anaphylm - The Pharma Letter
Aquestive Therapeutics Stock (AQST) Opinions on FDA Deficiency Notice - Quiver Quantitative
Aquestive announces FDA identified deficiencies in NDA for Anaphylm - TipRanks
Why Is Aquestive Therapeutics Stock (AQST) Down Today? - TipRanks
Aquestive stock falls after FDA cites deficiencies in Anaphylm application By Investing.com - Investing.com South Africa
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aquestive Therapeutics Inc 주식 (AQST) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
3.10 |
25,000 |
77,568 |
308,346 |
| Jung Cassie | Chief Operating Officer |
Oct 15 '25 |
Sale |
7.01 |
67,575 |
473,701 |
240,771 |
| Kraus Carl N | Chief Medical Officer |
Oct 15 '25 |
Sale |
7.00 |
20,272 |
141,904 |
282,475 |
| Boyd Peter E. | See Remarks |
Oct 15 '25 |
Sale |
7.00 |
10,000 |
70,000 |
268,323 |
1.30%
1.45%
자본화:
|
볼륨(24시간):